Granite Investment Partners LLC Acquires New Position in Certara, Inc. $CERT

Granite Investment Partners LLC bought a new position in shares of Certara, Inc. (NASDAQ:CERT) during the first quarter, HoldingsChannel.com reports. The firm bought 373,705 shares of the company’s stock, valued at approximately $2,130,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. raised its holdings in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Certara during the second quarter worth $83,000. Finally, Curated Wealth Partners LLC purchased a new stake in shares of Certara in the fourth quarter valued at $89,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Stephens dropped their target price on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird decreased their price target on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. Craig Hallum dropped their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Finally, Morgan Stanley cut their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and a consensus price target of $8.85.

Certara Stock Up 3.8%

Shares of NASDAQ CERT opened at $6.79 on Friday. The stock has a market capitalization of $1.06 billion, a PE ratio of -67.90 and a beta of 1.46. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The firm has a fifty day moving average of $5.68 and a 200-day moving average of $6.78. Certara, Inc. has a 52-week low of $4.45 and a 52-week high of $13.88.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. During the same period last year, the business posted $0.14 earnings per share. The company’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, analysts anticipate that Certara, Inc. will post 0.24 EPS for the current year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.